Hints and tips:
Related Special Reports
...to Laura Holding GmbH, as part of large outflows of money last year, the documents show....
...Here’s how it worked: Signa Development, one of three companies that oversaw the group’s investments, lent €125mn to Laura Finance Holding GmbH and another €190mn to Laura Holding GmbH, as part of large...
...Airbus also reaffirmed plans for a restructuring of its defence and space division, where it reported new charges of €300mn on “certain satellite development programmes”....
...“We don’t see any ceiling on expansion plans because we see a lot of road ahead with regards to market share and development.” However he refused to be drawn on an exact number....
...Among the factors that we will incorporate into the ranking process will be: Mentoring & training provided Infrastructure, eg offices, labs, software Legal assistance Business development advice Networking...
...Novavax said on Monday it remained “well-positioned to execute on its strategy”, which includes the development of experimental flu vaccines and an Omicron-targeted Covid shot....
...The plan on this site in Berlin is for a huge development of three towers. Pop KUDAMM is at best a glamorous distraction. At worst, a harbinger of Galeria’s demise....
...The Tübingen-based group has filed a lawsuit in a German court seeking “fair compensation” for alleged infringements of its intellectual property rights in the development of the Covid jab manufactured by...
...Research and development scientist Deniz Mert Bayram, 25, wears Officine Generale virgin wool Charlene jacket, €450, and matching trousers, €260....
...Rare diseases are sometimes protected under orphan-drug laws that encourage research and development by cutting tax and creating lengthy monopolies....
...Thomas Triomphe, who leads research and development at Sanofi’s vaccine business, said the results showed what the company has always said: that “flu is not Covid” — that flu vaccines need to be easy to...
...The problem at Berlin airport was that the project owner, Flughafen Berlin Brandenburg GMbH (FBB), had good operational capabilities but weak project capabilities....
...Rino Rappuoli, head of vaccines research and development at GSK, said the mRNA technology was a “strategic priority”....
...Take Chelmer GmbH. Run by a man called Richard Bunning, Chelmer GmbH is a shareholder of Mezzanine IX, a Luxembourg-based investment vehicle that back in 2017 was Adler’s largest shareholder....
...Then development setbacks led to delays, putting the company months behind its rivals....
...A third Covid-19 shot using GlaxoSmithKline’s adjuvant technology has entered a late-stage clinical trial as the UK drugmaker seeks to make up lost ground in the development of a coronavirus vaccine....
...According to a letter posted on Twitter by energy consultant Gonzalo Monroy, energy minister Rocío Nahle named Pemex the operator of the discovery and said the companies should present a development plan...
...“We’re the 1.5, last of the first generation,” said Greg Glenn, head of research and development at the biotech....
...In July, GlaxoSmithKline bought a 9 per cent stake and pledged €150m towards joint development of “next-generation” Covid-19 vaccines to tackle new variants....
...This is the story of how one of the most promising vaccine makers is trying to get back on track after development delays, the brain haemorrhage of its founder and a bizarre — possibly fictional — attempt...
...Germany’s CureVac has teamed up with the country’s largest pharmaceuticals company Bayer to accelerate the development and production of its Covid-19 vaccine....
...Development will begin immediately with a target of regulatory approval in 2022, the companies said. They plan to work on a joint approach to address “multiple emerging variants” in one jab....
...“This new collaboration builds on our existing relationship with CureVac and means that together, we will combine our scientific expertise in mRNA and vaccine development to advance . . . the development...
...This surprised some in the industry, who thought GSK the obvious partner for Oxford university’s vaccine development. In the event, it was AstraZeneca that worked with Oxford....
...The development of CureVac’s Covid-19 shot, however, has lagged behind German rival BioNTech, which received US authorisation last week, and Moderna, which applied for emergency approval last month....
International Edition